Biogen Inc. (BIIB)
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen is counting on its Alzheimer's drug, Leqembi, to jumpstart growth -- and sales are progressing in the United States. But European regulators consider the drug too risky.
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU's executive body, has a final say. But it almost always follows the drug regulator's recommendations.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen and Sage to scrap neurological disorder drug development after trial failure
Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Invites Shareholders In Biogen Inc Who Incurred Losses To Initiate Dialogue Please Be Aware Of The Deadline In This Matter
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2024.
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Contact Levi & Korsinsky by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Shareholders of Biogen Inc. (BIIB) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
FINAL BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
